BackPfizer Overview

Pfizer Other Current Liabilities

Latest other current liabilities for PFE: $23B.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$22.82B

Peer average

Loading

Pfizer Other Current Liabilities History

Loading

Pfizer vs. peers: Other Current Liabilities Comparison

Loading

Pfizer Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Pfizer (PFE) FAQ

As of the most recent data (March 2026), PFE shows a other current liabilities of $23B. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PFE's other current liabilities is now $23B (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Pfizer is outperforming or lagging.

Tracking PFE's other current liabilities over time shows whether Pfizer is scaling, shrinking, or reshaping that part of the business. The current reading is $23B In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Pfizer's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $23B) with ownership activity and broader fundamentals.

Pfizer's other current liabilities is $23B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.